<DOC>
	<DOCNO>NCT01674972</DOCNO>
	<brief_summary>The incretin effect impair patient type 2 diabetes mellitus ( T2DM ) , thus GLP-1 receptor agonist use treatment T2DM . Insulin resistance pathophysiologic hallmark non-alcoholic fatty liver disease ( NAFLD ) . The incretin effect patient NAFLD study . The aim study quantify GLP-1 secretion response oral glucose tolerance test ( oGTT ) patient NAFLD compare healthy control . The result study expand knowledge pathophysiology NAFLD serve rational potential future treatment strategy .</brief_summary>
	<brief_title>Glucose-induced Glucagon-like Peptide 1 ( GLP-1 ) Secretion NAFLD Patients Compared Healthy Controls</brief_title>
	<detailed_description>Primary endpoint : GLP-1 response oral glucose Secondary endpoint : glucose insulin response oral glucose challenge</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Biopsy proven NAFLD NASH additional concomitant liver disease T2DM alcohol consumption &gt; 40g/d male subject &gt; 20g/d female subject</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>NAFLD</keyword>
	<keyword>NASH</keyword>
	<keyword>GLP-1</keyword>
</DOC>